Viral states and immune competence in Epstein–Barr virus-positive diffuse large B-cell lymphoma: conditions for therapeutic targeting
Abstract
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) exhibits distinct viral expression, antigen-presentation and immune states that shape therapeutic opportunities. Malignant-cell viral attribution anchors diagnosis, while therapeutic activity depends on the target and mechanism being engaged. This critical narrative review integrates current disease definitions with viral and host dependencies, local immune organization, peripheral antiviral function and treatment evidence. Recent spatial studies identify latent membrane protein 1 (LMP1)-associated myeloid niches and heterogeneous human leukocyte antigen (HLA) expression, including increased HLA expression in LMP1-positive compared with LMP1-negative malignant B cells. Peripheral studies report reduced peptide-pool interferon-γ responses and increased CD4 responses to autologous lymphoblastoid cells, emphasizing that stimulus and responding cell population define the measurement. These observations connect viral state with specific opportunities to improve recognition, effector function and tumor access. Virus-specific T cells require a relevant antigen and a shared restricting HLA allele; surface-antigen redirection uses a different recognition route; checkpoint blockade acts on recoverable immune responses; and induction–antiviral combinations require an induced cell fraction with functional drug activation and additional tumor killing. Small clinical series demonstrate activity in selected settings, while negative comparative findings and posted trial outcomes define the limits of that evidence. Studies with paired tissue and blood sampling, functional perturbation and prospectively specified biomarker-by-treatment analyses can establish which biological measurements improve treatment selection. The resulting research agenda links disease-specific viral and immune biology to measurable therapeutic requirements.
Related
- CD10-Positive Extranodal Marginal Zone Lymphoma of the Thyroid Arising in Hashimoto’s Thyroiditis: A Rare Diagnostic Challenge
- NPM1::ALK fusion-derived circular RNAs drive aggressiveness in ALK-positive anaplastic large cell lymphoma
- EBV-positive Hodgkin lymphoma with an immunosuppressive microenvironment during guselkumab (interleukin-23 inhibitor) therapy for chronic plaque psoriasis
- Associations Between Selected Autoimmune and Immune-Mediated Conditions and Lymphoma Among Hospitalized Adults: A National Inpatient Sample Analysis
- Progesterone Beyond Pituitary Suppression in Assisted Reproduction: Peripheral Signalling, Gamete Biology, Endometrial Competence and Precision Therapeutic Use
BibTeX
@article{tang2026viral,
title = {{Viral states and immune competence in Epstein–Barr virus-positive diffuse large B-cell lymphoma: conditions for therapeutic targeting}},
author = {Xinzhu Tang and Qiuhui Wu and He Li and Ting Niu},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.2027472},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2027472},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Viral states and immune competence in Epstein–Barr virus-positive diffuse large B-cell lymphoma: conditions for therapeutic targeting
AU - Xinzhu Tang
AU - Qiuhui Wu
AU - He Li
AU - Ting Niu
PY - 2026
DA - 2026/11/10
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2027472
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2027472
AB - Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) exhibits distinct viral expression, antigen-presentation and immune states that shape therapeutic opportunities. Malignant-cell viral attribution anchors diagnosis, while therapeutic activity depends on the target and mechanism being engaged. This critical narrative review integrates current disease definitions with viral and host dependencies, local immune organization, peripheral antiviral function and treatment evidence. Recent spatial studies identify latent membrane protein 1 (LMP1)-associated myeloid niches and heterogeneous human leukocyte antigen (HLA) expression, including increased HLA expression in LMP1-positive compared with LMP1-negative malignant B cells. Peripheral studies report reduced peptide-pool interferon-γ responses and increased CD4 responses to autologous lymphoblastoid cells, emphasizing that stimulus and responding cell population define the measurement. These observations connect viral state with specific opportunities to improve recognition, effector function and tumor access. Virus-specific T cells require a relevant antigen and a shared restricting HLA allele; surface-antigen redirection uses a different recognition route; checkpoint blockade acts on recoverable immune responses; and induction–antiviral combinations require an induced cell fraction with functional drug activation and additional tumor killing. Small clinical series demonstrate activity in selected settings, while negative comparative findings and posted trial outcomes define the limits of that evidence. Studies with paired tissue and blood sampling, functional perturbation and prospectively specified biomarker-by-treatment analyses can establish which biological measurements improve treatment selection. The resulting research agenda links disease-specific viral and immune biology to measurable therapeutic requirements.
SN - 2234-943X
ER -